Tonix Pharmaceuticals Holding C
TNXP
Positions held
Your positionsTNXP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $124.86M | Enterprise value | -$50.10M | Trailing P/E | — | Forward P/E | -0.92 |
| PEG | — | Price / book | 0.55 | Beta | 1.79 | Dividend yield | 0.00% |
| Revenue growth | 5.8% | Earnings growth | — | Gross margin | 83.8% | Operating margin | -3.1% |
| Profit margin | 0.0% | ROE | -81.8% | ROA | -46.8% | Debt / equity | 0.01 |
| Current ratio | 6.61 | Free cash flow | -$95.76M | Analyst recommendation | strong_buy | Mean target | $44.50 |
| 52w high | $23.06 | 52w low | $7.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $13.5M | $6.9M | $5.4M | $3.3M | $2.0M | — |
| Op margin | -309.6% | -603.9% | -894.5% | -975.2% | -1364.4% | — |
| Net income | -$40.6M | -$40.2M | -$46.9M | -$32.0M | -$28.3M | — |
| Gross margin | 94.8% | 77.1% | 80.4% | 58.4% | -63.8% | — |
| Gross profit | $12.8M | $5.3M | $4.3M | $1.9M | -$1.3M | — |
| Operating income | -$41.9M | -$41.5M | -$48.2M | -$32.1M | -$27.3M | — |
- Revenue +97% vs prior quarter ($14M vs $6.9M).
- Gross margin 94.8% (was 77% prior quarter).
- Operating margin expanded to -309.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | $0.0M | — |
| Op margin | -936.1% | -744.5% | -1523.9% | — | — |
| Net income | -$124M | -$130M | -$117M | -$110M | — |
| Gross margin | 49.3% | 23.1% | 39.0% | — | — |
| Gross profit | $6.5M | $2.3M | $3.0M | $0.0M | — |
| Operating income | -$123M | -$75.2M | -$118M | -$112M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
2026-09-12 · Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
2026-09-08 · Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
2026-09-02 · TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
2026-09-02 · Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
2026-08-18 · Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
2026-08-17 · Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
2026-08-10 · Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...
2026-08-10 · Tonix Pharmaceuticals Q2 Earnings Call Highlights
2026-08-05 · Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-07-27 · Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Price (daily)
Full chart · RSI · MACD · patterns